The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer.
BACKGROUND
The positron emission tomography (PET) with F18 17beta-estradiol (FES) has good imaging for assessment of estrogen receptor in breast cancer.


METHODS
We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F-18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic response, and hysteroscopy showed no abnormal finding.


CONCLUSIONS
To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET about the hormone therapy.
Yoshida
Yoshio
Y
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Matsuoka-cho, Yoshida-gun, Fukui-ken 910-1193, Japan. yyoshida@fmsrsa.fukui-med.ac.jp
Kurokawa
Tetsuji
T
Sawamura
Yoko
Y
Shinagawa
Akiko
A
Okazawa
Hidehiko
H
Fujibayashi
Yasuhisa
Y
Kotsuji
Fumikazu
F
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D000328:Adult; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005462:Fluorine Radioisotopes / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use; D006801:Humans; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000627:therapeutic use
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D004958:Estradiol; C043436:16-fluoroestradiol